BioVaxys Technology Corp.
BIOV
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.74% | 139.99% | 205.50% | 73.11% | 145.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.74% | 139.99% | 214.62% | 79.85% | 122.99% |
| Operating Income | -6.74% | -139.99% | -214.62% | -79.85% | -122.99% |
| Income Before Tax | 23.55% | -131.77% | -296.27% | -12.90% | 59.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 23.55% | -131.77% | -296.27% | -12.90% | 59.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 23.55% | -131.77% | -296.27% | -12.90% | 59.08% |
| EBIT | -6.74% | -139.99% | -214.62% | -79.85% | -122.99% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 42.39% | -67.19% | -208.71% | 32.38% | 72.68% |
| Normalized Basic EPS | 23.24% | -65.00% | -81.74% | 8.12% | 84.82% |
| EPS Diluted | 42.39% | -67.19% | -208.71% | 32.38% | 72.68% |
| Normalized Diluted EPS | 23.24% | -65.00% | -81.74% | 8.12% | 84.82% |
| Average Basic Shares Outstanding | 32.46% | 38.42% | 80.52% | 67.02% | 49.90% |
| Average Diluted Shares Outstanding | 32.46% | 38.42% | 80.52% | 67.02% | 49.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |